zithromax and Hearing-Loss

Epidemiologic, laboratory, animal, and clinical studies suggest that there is an association between Chlamydia pneumoniae infection and atherogenesis. We evaluated the efficacy of one year of azithromycin treatment for the secondary prevention of coronary events.. In this randomized, prospective trial, we assigned 4012 patients with documented stable coronary artery disease to receive either 600 mg of azithromycin or placebo weekly for one year. The participants were followed for a mean of 3.9 years at 28 clinical centers throughout the United States.. The primary end point, a composite of death due to coronary heart disease, nonfatal myocardial infarction, coronary revascularization, or hospitalization for unstable angina, occurred in 446 of the participants who had been randomly assigned to receive azithromycin and 449 of those who had been randomly assigned to receive placebo. There was no significant risk reduction in the azithromycin group as compared with the placebo group with regard to the primary end point (risk reduction, 1 percent [95 percent confidence interval, -13 to 13 percent]). There were also no significant risk reductions with regard to any of the components of the primary end point, death from any cause, or stroke. The results did not differ when the participants were stratified according to sex, age, smoking status, presence or absence of diabetes mellitus, or C. pneumoniae serologic status at baseline.. A one-year course of weekly azithromycin did not alter the risk of cardiac events among patients with stable coronary artery disease.

Topics: Aged; Anti-Bacterial Agents; Azithromycin; Chlamydophila Infections; Chlamydophila pneumoniae; Coronary Disease; Double-Blind Method; Female; Hearing Loss; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Prospective Studies

Topics: Age Factors; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Bronchodilator Agents; Cardiovascular System; Comorbidity; Disease Progression; Drug Resistance, Multiple, Bacterial; Hearing Loss; Humans; Macrolides; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Risk Assessment

Topics: Antibiotic Prophylaxis; Azithromycin; Bronchodilator Agents; Cardiovascular System; Drug Resistance, Multiple, Bacterial; Hearing Loss; Humans; Macrolides; Pulmonary Disease, Chronic Obstructive

Topics: Antibiotic Prophylaxis; Azithromycin; Bronchodilator Agents; Cardiovascular System; Drug Resistance, Multiple, Bacterial; Hearing Loss; Humans; Macrolides; Pulmonary Disease, Chronic Obstructive

Delayed and reversible hearing loss occurred in a 55-year-old male patient with murine typhus infection. The patient had the initial symptoms of headache, fever and chills, followed by the occurrence of bilateral hearing loss on day 9 from fever onset. Murine typhus was diagnosed with a high IgM titre by indirect immunofluorescence assay. After treatment with azithromycin and prednisolone, the fever and other symptoms subsided gradually and bilateral hearing loss improved 3 weeks later. Though an adverse reaction to azithromycin could not be ruled out, delayed onset of hearing loss was more likely a complication of murine typhus, mainly because the hearing loss did not occur during the azithromycin usage period. Although hearing loss due to murine typhus is rare, clinicians should be alert to the existence of such a delayed complication.

Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Azithromycin; Fluorescent Antibody Technique, Indirect; Hearing Loss; Humans; Immunoglobulin M; Male; Middle Aged; Prednisolone; Typhus, Endemic Flea-Borne